Walleye Capital LLC Invests $1.17 Million in Protara Therapeutics, Inc. (NASDAQ:TARA)

Walleye Capital LLC purchased a new position in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 220,814 shares of the company's stock, valued at approximately $1,166,000. Walleye Capital LLC owned approximately 1.07% of Protara Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Geode Capital Management LLC raised its stake in Protara Therapeutics by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after purchasing an additional 9,553 shares in the last quarter. Commonwealth Equity Services LLC raised its position in shares of Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after buying an additional 17,572 shares in the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Protara Therapeutics by 12.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after acquiring an additional 22,301 shares during the last quarter. Bailard Inc. purchased a new position in Protara Therapeutics in the fourth quarter worth about $157,000. Finally, XTX Topco Ltd purchased a new position in Protara Therapeutics in the third quarter worth about $60,000. Institutional investors own 38.13% of the company's stock.

Protara Therapeutics Stock Down 2.1 %

TARA stock traded down $0.09 during trading on Thursday, hitting $4.11. The company had a trading volume of 345,138 shares, compared to its average volume of 770,820. The company has a 50 day simple moving average of $4.03 and a 200-day simple moving average of $3.94. The firm has a market capitalization of $151.11 million, a P/E ratio of -1.46 and a beta of 1.60. Protara Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09. Sell-side analysts forecast that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Insider Buying and Selling at Protara Therapeutics

In other news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the sale, the insider now owns 98,861 shares of the company's stock, valued at $447,840.33. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Thursday, March 6th. Scotiabank initiated coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price target for the company. Lifesci Capital began coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $20.40.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.